Release date: 2015-10-27
American scientists discover blood antibody detection technology for predicting Alzheimer's disease
Diseases can result in changes in the characterization of autoantibodies, and changes in the characterization of autoantibodies can serve as biomarkers that reveal the presence of disease. Recently, researchers such as Dr. Robert Nagele of the University of Rowe School of Orthopaedics in the United States have discovered through this theory that the detection of changes in the level of an antibody in the blood can predict whether Alzheimer's disease will occur. The discovery of this technique has made it possible to prevent and treat Alzheimer's disease.
Renault read the news with you : I was most impressed with Alzheimer's blood antibody detection technology and put it in the headlines. One of the reasons is that the treatment is not ill. New diagnostic techniques offer the potential for disease prevention and early treatment. The second reason is that Daosheng is one, two is born, two is three, and three are born. It is conceivable that this discovery will open up more ideas and more prosperous innovations in the understanding, treatment and prevention of Alzheimer's disease.
EMA recommends Kite Pharmaceutical's KTE-C19 treatment to regain blood status as a rare drug
Recently, Kite Pharmaceuticals announced that the company's KTE-C19 has been recommended by the EMA Rare Diseases Treatment Association (COMP) for lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and The rare drug status of follicular lymphoma (FL). KTE-C19 is a CAR-T cell therapy. Previously, KTE-C19 has been treated in the European Union and the United States for the treatment of diffuse large B-cell lymphoma (DLBCL) and the rare disease status of primary mediastinal B-cell lymphoma (PMBCL) and mantle cell lymphoma (MCL).
Renault reads the news with you: CAR-T treatment technology is known as a breakthrough technology for the treatment of cancer. Since its establishment in the early 1990s, it has achieved great results in the treatment of hematological cancer.
Novartis and Luc accelerate the development of NMDA receptor modulator NAMs for the treatment of depression
Luc Therapeutics Biotech has reached a partnership agreement with Novartis to accelerate the development of selective NMDA receptor negative sex regulators (NAMs) for new treatments for depression. Luc has granted the exclusive license to the company's NMDA receptor negative sex regulator NR2B NAMs to Novartis, and Novartis will participate in the development of this drug. NR2B NAMs are different from all antidepressant drugs currently on the market, and their therapeutic effects are of an inter-generational significance.
Renault read the news with you: Novartis and Luc Therapeutics have accelerated their cooperation, indicating that the winds of depression treatments will transfer the NMDA receptor negative sex modifier NR2B NAMs, which I have translated.
The survey showed that 83% of patients do not need to undergo chemotherapy-induced nausea and vomiting
A study of chemotherapy-induced nausea and vomiting (CINV) by the Society for Blood/Oncology Pharmaceuticals (HOPA) and Eisai's global chemotherapy patients and pharmacists found that 83% of patients receiving chemotherapy developed chemotherapy. The nausea and vomiting response occurs in 95% of patients with cancer surgery. HOPA pointed out that if these patients and pharmacists know how to prevent and early intervention in the treatment of CINV, then 83% of patients do not need to experience such pain. The survey pointed out that one-third of patients had insufficient cognition of CINV. They believed that CINV was a sign of the onset of chemotherapy drugs, and 4/5 patients who experienced CINV agreed that the symptoms of CINV were controlled if vomiting did not occur. CINV has a great impact on patients' daily lives. 3/4 Patients who experience CINV believe that CINV will affect their further treatment of cancer, 56% of patients have their personal plans affected, 46% have changed their eating habits, and 43% have cancelled For daily exercise, 38% need sick leave.
Renault read the news with you: If it is not the Eisai company's research, I really don't know that chemotherapy-induced nausea and vomiting will be so neglected, but this news is not the Eisai company for chemotherapy anti-vomiting agent Akynzeo [Palonosetron ( Palonosetron)/Netupitant] A prelude to sales success?
FDA requires Shire to supplement additional clinical data for dry eye disease drug lifitegrast III
Recently, the FDA issued a complete response letter (CRL) to Shire to require the company to provide more clinical data on the dry eye treatment drug lifitegrast to meet the drug approval requirements. In the previous application, the company provided two Phase II clinical studies data and two Phase III clinical studies (OPUS-1 and OPUS-2, respectively) to the FDA. The company is currently conducting a Phase III clinical study called OPUS-3. If the study reaches the clinical end-point goal, it will be expected to meet the FDA's requirements. The company intends to re-apply to the FDA in the first quarter of next year.
Renault read the news with you: Although lifitegrast is currently frustrated, I still believe that it will be approved in the end because the clinical demand for dry eye treatments is very large.
Female Viagra Addyi is now available
The world's first drug developed by Sprout Pharmaceuticals to help women improve their low libido, Flibanserin (Addyi) has recently been listed in the United States. Flubensin was originally used to treat depression and was later found to help improve female libido. The mechanism of action of flurbiner is not fully understood, but the researchers found that it can increase the secretion of dopamine, a neurotransmitter in the brain. Since 2010, flubanserine has been controversial due to the risk of drug use, and has been rejected by the FDA twice for approval. In June of this year, an advisory committee of the FDA recommended that listings be allowed under a series of risk prevention measures. Although the efficacy of flurbine is not significant, it is meaningful for some patients and women need one.
Professor Tang Note: This product is controversial in the United States and voted 18 to 6 on the advisory board. This product can cause social problems and can only be used in the United States under restricted procedures. This product is not suitable for China's national conditions, society and culture. The instruction manual is for understanding.
Renault read the news with you: The female Viagra Addyi went public, so I have to feel that the Americans are really temperamental. We have always been half-faced, and we want to say that we still have a rest, but it is a good autumn.
US FDA approves Relypsa's Veltassa (patiromer oral suspension) for the treatment of hyperkalemia
Recently, the US FDA approved Relypsa's Veltassa (patiromer oral suspension) for the treatment of hyperkalemia. Veltassa is a powder that can be combined with potassium ions in the gastrointestinal tract to reduce potassium absorption when the patient swallows it with water. In clinical trials, Veltassa can reduce the hyperkalemia symptoms in patients with chronic kidney disease after using the renin-angiotensin-aldosterone system inhibitor. In clinical trials, the most common adverse reactions of veltassa are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort, and flatulence. Because veltassa has a slower onset, it cannot be used as an emergency medication for hyperkalemia. Veltassa has a black box warning, because it can be combined with other drugs to reduce its absorption, so the FDA recommends that it be taken at least six hours apart from other oral administration.
US FDA approves the treatment of new plaque psoriasis Enstilar
The US FDA recently approved a foam containing calcipotriol and betamethasone dipropionate (Enstilar, LEO Pharmaceuticals) for topical treatment of plaque psoriasis in adults.
Enstilar is a non-alcoholic spray containing both of these drugs for topical use in the treatment of plaque psoriasis. Enstilar is used once a day for 4 weeks as a course of treatment. The patient should stop using the drug after the condition has healed, and the maximum use per four days does not exceed 60g.
Next, Renault specifically screened six important domestic news and sent it to readers who have not yet had time to browse domestic medical news. Among them, tobacco control was listed as one of the problems that China must solve in order to achieve the goal of medical reform. It seems that sooner or later, it’s coming soon!
The “13th Five-Year†Health Plan identifies four key projects
The 2nd Beijing-Tianjin-Hebei Regional Medical Development Academic Conference was held in Beijing. According to the relevant person in charge of the Planning Department of the National Health and Family Planning Commission, during the 13th Five-Year Plan period, the four major projects have been identified in the medical and health service plan: Focus on the hospital, strengthen the construction of grassroots medical and health service system, appropriately expand the bed size of grassroots institutions; focus on improving the level of medical services for children in hospitals and critically ill medicines; and strengthen special hospitals and county level hospitals for children and above. We will build weak links such as psychiatric hospitals; further strengthen the construction of population health information platforms at the national, provincial, municipal, and county levels, and build a population health information network that links, interconnects, and shares information across the country. (health report)
"Lancet": How can China achieve the goal of medical reform?
"Lancet" has always paid attention to China's medical reform. The following content is translated from the latest "Lancet" China topic. It talks about the challenges faced by China's medical reform and the problems that need to be solved in order to achieve the grand goal. It generally comes down to: training general practitioners, strengthening medical education, tobacco control, and strengthening clinical research efforts and capital investment. (医脉通)
The Health and Family Planning Commission announced the first batch of 56 day surgery recommended!
The “fast and efficient†day surgery is being favored by more hospitals. At the same time, it is more important to strengthen the standardization and promote the healthy development of day surgery. Which diseases are suitable for day surgery? At the Third National Day Surgery Academic Annual Meeting held on October 15-16, Professor Zhang Zhenzhong, Chairman of the China Day Surgery Cooperation Alliance and Honorary Director of the National Health and Family Planning Research Center It was revealed that the first batch of day surgery procedures recommended to the whole country were 56. In terms of classification, it is divided into 15 digestive systems, 10 orthopedics, 7 males, 6 ophthalmology, 5 otolaryngology, 5 urinary systems, 4 endocrine, 2 gynecology, and 2 oral. Day surgery generally refers to the operation or operation performed by the patient within one day (24 hours). Since the introduction of China in 2001, day surgery has gradually been favored by hospitals. Especially in recent years, the development is more rapid. (Xinhua)
24 hospitals selected for the first batch of inpatient medical training demonstration bases (list)
On October 16, the official website of the Health Planning Commission released the "Notice on Promulgating the List of Resident Standardized Training Demonstration Bases" (hereinafter referred to as the Notice), Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Peking University First Hospital, Capital Medical University General Hospital, China First Affiliated Hospital of Medical University, First Hospital of Jilin University, First Affiliated Hospital of Harbin Medical University, Zhongshan Hospital of Fudan University, Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Changhai Hospital of Second Military Medical University, Jiangsu Provincial People's Hospital, Zhejiang University First Affiliated Hospital of Medical College, Fujian Provincial Hospital, Qilu Hospital of Shandong University, Union Hospital of Tongji Medicine, Huazhong University of Science and Technology, Xiangya Hospital of Central South University, First Affiliated Hospital of Sun Yat-sen University, Children's Hospital of Chongqing Medical University, West China Hospital of Sichuan University 24 units of Xijing Hospital of the Fourth Military Medical University, the First Affiliated Hospital of Xinjiang Medical University, Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine (Chinese Medicine), Longhua Hospital of Shanghai University of Traditional Chinese Medicine (Chinese Medicine) and Jiangsu Provincial Hospital of Traditional Chinese Medicine (Chinese Medicine) were identified as Resident standardization training (biological exploration)
Lancet: the prevalence of acute kidney injury in China cannot be ignored.
Recently, Yang Li, chief physician of the Department of Nephrology, Peking University First Hospital, published a research article on "The Acute Kidney Injury in China: A Cross-sectional Study" on the Lancet. The prevalence of acute kidney injury in China cannot be ignored, and the diagnosis and treatment are serious. Insufficient problems require clinicians to raise awareness of the risk. The study was completed at 44 research centers and evaluated more than 2 million patients in 44 university hospitals or local hospitals in 22 provinces in mainland China in 2013. According to estimates, in 2013, there were 1.4 million to 2.9 million patients with acute kidney injury in China, and the total medical cost was about 13 billion US dollars. The hospital mortality rate for acute kidney injury was 12.4%. In 2013, an estimated 700,000 patients with acute kidney injury died in China. However, only 16.7% of patients with acute kidney injury can be found through the ICD-10 disease code search. Therefore, acute kidney injury has become a huge medical burden in China, and there are serious problems in diagnosis and treatment. (Medical Tribune)
"Chinese Colorectal Cancer Treatment and Treatment Regulations (2015 Edition)" released
The “National Colorectal Cancer Diagnosis and Treatment Specification (2015 Edition)†(hereinafter referred to as the “New Editionâ€), which was led by the Medical and Health Administration of the National Health and Medical Council, was revised and completed. The new edition of the Code firstly counted the incidence and mortality of colorectal cancer in China (23.03/100,000, 11.11/10,000), and found that urban morbidity and mortality were higher than in rural areas, and the incidence of colon cancer increased significantly. . The new edition of the Code states that the state of liver function can be used as an important indicator for assessing patient status and predicting prognosis. The new edition of the Code emphasizes the general principles of medical treatment, pays attention to improving patients' quality of life and comorbidities, and emphasizes that the best supportive treatment should be carried out throughout the patient's treatment; the chemotherapy regimen is adjusted, and the initial pre-treatment assessment is emphasized in rectal cancer radiotherapy. The importance of it; it is recommended that patients with advanced disease can choose local treatment such as interventional therapy, intratumoral injection, physical therapy or traditional Chinese medicine treatment without proper treatment.
Source: New Kangjie
Micro-prismatic Reflective Tape
Diamond Reflective Tape,Transparent Reflective Tape,Diamond Grade Reflective Tape,Diamond Grade Reflective Sheeting
Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.jerrytapes.com